IMAGET1D

Home

About IMAGET1D

About IMAGET1D

Have you been diagnosed with type 1 diabetes and recently enrolled in an eligible* diabetes study?

You may be eligible to come to Boston for a research study of MRI imaging of the pancreas as part of the IMAGET1D study. This will help contribute to a better understand of the natural progression of type 1 diabetes and how various therapies affect it.

Welcome to IMAGET1D!

IMAGET1D stands for Imaging with MAGnetic resonance in T1D.
The goal of this study is to use a magnetic resonance imaging (MRI) based technique to monitor changes in the pancreas associated with the development of type 1 diabetes. MRI imaging may reveal changes associated with diabetes before other “downstream” measures like hemoglobin A1C or c-peptide.

How it works

Macrophages are cells of the immune system that are present when there is autoimmune destruction and inflammation in the pancreas of a person with type 1 diabetes. Changes in the blood vessels have also been identified. In order to better see the inflammation, the iron-containing drug ferumoxytol (Feraheme®) is given as an intravenous infusion. This drug goes out of “leaky” blood vessel and is taken up by the macrophages, so there is more uptake of ferumoxytol where there is more inflammation. An MRI is done at just before infusion of ferumoxytol, and then again approximately 48 hours after the infusion. By comparing the uptake on the MRIs before and after the infusion, researchers get a sense of how much inflammation is present in the pancreas. Ferumoxytol is FDA-approved for use in adults with iron deficiency anemia due to chronic kidney disease. It is considered experimental for imaging.

Participating in the IMAGET1D Research Study:

All imaging visits are conducted at the Massachusetts General Hospital in Boston, MA. Duration of participation depends upon the diabetes study in which you are participating. Generally, each imaging visit will consist of two separate MRIs, which will be done about 48 hours apart. Blood may also be collected at each visit.

For those in the EXTEND study, all participants will be asked to participate over a 1-year period, which will include three separate imaging visits in Boston, MA. The initial imaging visit will occur 7 days prior to receiving the study drug, and will serve as a baseline. MRI imaging will be repeated at 6 months (at the end of the treatment course with the EXTEND study drug), and at 12 months. Regardless of whether or not any individual participant receives the study drug or placebo, all are eligible for IMAGET1D.

*see the Are you eligible? section

For more information, call us toll-free at 1-888-813-8669 or e-mail us at IMAGET1D@mgh.harvard.edu

Revised on 2015-11-25 17:44:23 UTC